FY2025 Earnings Estimate for ATXS Issued By Lifesci Capital

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Research analysts at Lifesci Capital reduced their FY2025 earnings per share (EPS) estimates for Astria Therapeutics in a report released on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky now forecasts that the biotechnology company will post earnings per share of ($1.97) for the year, down from their prior estimate of ($1.95). The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share.

ATXS has been the topic of a number of other reports. Citizens Jmp raised Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Wedbush reaffirmed an "outperform" rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $26.67.

Astria Therapeutics Stock Performance

ATXS traded up $0.01 during trading on Friday, reaching $6.49. The stock had a trading volume of 368,454 shares, compared to its average volume of 453,733. The stock has a market cap of $366.26 million, a PE ratio of -3.11 and a beta of 0.69. Astria Therapeutics has a one year low of $5.73 and a one year high of $16.90. The business has a 50-day moving average of $7.10 and a 200-day moving average of $9.46.

Remove Ads

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics in the fourth quarter worth about $41,000. Tower Research Capital LLC TRC lifted its holdings in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Astria Therapeutics during the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC purchased a new position in shares of Astria Therapeutics during the fourth quarter valued at approximately $65,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Astria Therapeutics during the fourth quarter valued at approximately $91,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.